Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26. Mai 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23. Mai 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
08. Mai 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022Management updates 2023 financial guidance, now anticipating...
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28. April 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended...
Y-mAbs Announces Presentation of Naxitamab data at AACR
18. April 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05. April 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
30. März 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022DANYELZA conditional marketing authorization granted in China...
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
21. März 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December...
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
02. Februar 2023 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
04. Januar 2023 16:01 ET
|
Y-mAbs Therapeutics, Inc
Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million;Estimated total cash burn for 2023, including restructuring...